41 results about "Acyl chain" patented technology

The methods and compositions disclosed herein concern the synthesis of a novel class of “two-headed” phospholipid-phosphoinositide hybrids possessing a carbon backbone, such as 2,3-diacylthreitol, erythritol or a synthetic module. The second phospholipid head group allows introduction of a biochemical or chemical moiety in a position orthogonal in space to those occupied by the phosphoinositide head group and the two acyl chains. The diacyl moieties allow for the incorporation of Pea-PIP₂ into a lipid bilayer, while the Ptdlns(4,5)P₂ moiety in the aqueous layer is specifically recognized by lipid binding proteins. In alternative embodiments of the invention, reporters, for example biotin, fluorophores and/or spin labels, are attached to the free amino group of the head groups of such molecules to specifically target the reporters to the lipid-water interface.

The subject invention lies in the field of vaccines. Specifically new compounds that can be used as adjuvants are provided. Recombinant LPS having a reduced number of secondary acyl chains per molecule of LPS vis a vis the corresponding non modified LPS molecule, said secondary acyl chains being bound to primary acyl chains, said primary acyl chains being bound to the glucosamine of said recombinant LPS molecule, said recombinant LPS being homogenous in acylation pattern is an example of such a compound. Also recombinant LPS having a phosphate group attached to the glucosamine at the non reducing end of the LPS molecule and a phosphate group attached to the glucosamine at the reducing end of the molecule per recombinant LPS molecule provides a further example.

The invention relates to a method for the enzymatic elimination of the N-acyl side chain from lipopeptides to form the corresponding nucleus, wherein the lipopeptide is prepared by fermentation, the lipopeptide being bound to the cells of the biomass, and the biomass is removed with the adhering lipopeptide, the biomass with the adhering lipopeptide is resuspended in an aqueous system, a suitable deacylase is added in dissolved or solid form to the suspension of the biomass, and the corresponding nucleus is formed, and the nucleus is optionally isolated and purified, wherein the lipopeptide obtained by fermentation is reacted after the end of the fermentation as cell-bound biomass without further purification directly with a deacylase, whereby the N-acyl chain linked via an amide linkage is eliminated.

The present invention relates to methods for large-scale production of conjugated fatty acids, especially conjugated linoleic acids in plants. More specifically, the present invention relates to genes identified from Calendula officinalis coding for a conjugase and its related enzyme, a .DELTA.12 desaturase, and utilization of them for large scale production of conjugated linoleic and linolenic acids in plants. The genes encoding a conjugase can introduce two conjugated double bonds at 8 and 10 positions, and a .DELTA.12 desaturase can introduce a double bond at 12 position of acyl chains. The constructs containing these genes can be transferred to plants with different substrate profiles, which allows for the production of conjugated linoleic acids (18:2, .DELTA.8, .DELTA.10) and linolenic acids (18:3, .DELTA.8, .DELTA.10, .DELTA.12) in plant seeds on a commercial scale.

A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional HtrB protein, resulting in a mutant that lacks one or more secondary acyl chains and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, or the endotoxin isolated therefrom, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.

A product and the use thereof to stimulate and/or modulate immune response in animals and humans, comprising lipids having a glycerol backbone carrying at least one alkyl or acyl chain, wherein the lipid is phospholipid, glycolipid or neutral lipid, saturated or unsaturated, and the number of carbon atoms in the hydrocarbon tails lies between (10 and 22) inclusive, the lipids being defined as esters of glycerol (propane 1,2,3-triol) with fatty acids, also including 1,2-di-O-acylglycerol joined at oxygen (3) by a glycosidic linkage to a carbohydrate, also derivatives of glycerol in which one hydroxy group, commonly but not necessarly primary, is esterified with fatty acids, and execluding those organic compounds consisting of a trisaccharide repeating unit with oligosaccharide side chains and acyl or amine linked fatty acids.

The invention relates to a liquid nutrition comprising short chain fatty acyl chains, polyunsaturated fatty acyl chains, vegetable oil and a non-digestible, fermentable saccharide. The composition is particular suitable for use as an infant nutrition. The composition is also suitable for treatment and/or prevention of gut barrier related disorders.

A calorimetric detector for chemical and biological agents or toxins is made of a giant unilamellar vesicle (GUV) having a membrane bilayer which is polymerized to stabilize the giant unilamellar vesicle and to provide extended conjugated polymer backbone, and the GUV has at least one incorporated molecular recognition site for the chemical and biological agents or toxins. The GUVs are about 10-300 microns and preferably made of a polymerizable diacetylenic GUV where the acyl chains are crosslinked. When the agents or toxins bind to the recognition site the detector exhibits a color change. The detector can be used in a colorimetric detector apparatus where the samples can be present in air or in water.

An injectable polymer-lipid blend is provided as a localized drug delivery system for a pharmaceutically active agent. The blend may be prepared from a chitosan-based material, fatty acid and phospholipid. The chitosan-based material may be a water soluble chitosan derivative. The fatty acid may be a fatty acid or a fatty aldehyde, such as laurinaldehyde, having an acyl chain length of C8-C16. The rheological properties of the blend relates to the ratio of the components and to the acyl chain length of the fatty acid. The injectable system is well suited for the delayed release of pharmaceutically active agents in the treatment of cancer and other diseases requiring localized drug delivery.

The invention discloses escherichia coli for synthesizing monophosphate lipoid A containing only three fatty acid chains, and belongs to the field of genetic engineering and bioengineering. According to the invention, coding secondary acyl chain transferase genes lpxL, lpxP and lpxM on an escherichia coli HW003 genome are knocked out. The invention provides escherichia coli with a simplified lipoid A structure which lacks 1-site phosphoric acid, 3-site primary acyl chains, 2'site secondary acyl chains and 3 'site secondary acyl chains compared with wild type lipoid A. The lipoid A structure provides a method for identifying Gram-negative fungus lipoid A secondary acyl chain transferase gene functions in escherichia coli.

The invention relates to a foamable or whippable food composition, in particular a cream, comprising at least 12 wt. % fat, protein, water, a citric acid ester of a mono- or diglyceride of one or more fatty acids comprising an unsaturated acyl chain and a lactic acid ester of a mono- or diglyceride of one or more fatty acids, the total content of substances other than water being at least 15 wt. % of the total weight of the composition.

Provided are modified lipid compounds and their use in the formation of lipid assemblies. Also provided are lipid assemblies including (a) an amphoteric lipid including in covalent association with (i) one or more acyl chains; (ii) one or more weak base moiety; (iii) one or more weak acid moiety; the lipid assembly also including (b) one or more additional lipids, at least one of which being a zwitterionic lipid. In some embodiments, the amphoteric lipid is a compound including (a) a tri-functional moiety; (b) two non-phosphate lipid chains associated with two of the functional moieties of said tri-functional moiety; (c) optionally a spacer moiety associated with the third of the functional moieties of said tri-functional moiety; and (d) a polyalkylamine optionally including a short peptide with one to several carboxylic acid residues. Further provided are the uses of the lipid assembly, inter alia, for transfection or cancer treatment.

The invention belongs to the technical field of molecular biological prevention and treatment, and finds that an N-acyl homoserine lactone acyltransferase coding gene is cloned through a molecular biological technology on the basis that pseudomonas nitroreducens HS-18 can efficiently degrade AHLs signal molecules with the acyl chain length of C4-C14 in early-stage research. According to the invention, in early-stage research, on the basis that pseudomonas nitroreducens HS-18 can efficiently degrade AHLs signal molecules with C4-C14 acyl chains, an N-acyl homoserine lactone acyltransferase coding gene is cloned through a molecular biological technology. The gene has broad-spectrum and efficient quenching activity on AHLs with different side chain lengths and different side chain substituted band groups. By expressing the N-homoserine lactone quenching gene in AHLs pathogenic pathogenic bacteria, the motility of the pathogenic bacteria, biofilm formation and generation of virulence factors such as extracellular enzymes can be remarkably weakened, and the pathogenicity of the pathogenic bacteria to host plants is remarkably weakened.